CLopidogrel, Aspirin and RIvaroxaban after revascularisation with angioplasTY for limb-threatening Peripheral Arterial Disease (CLARITY PAD)

orth Bristol NHS Trust0 个研究点目标入组 1,239 人开始时间: 2024年8月22日最近更新: 2024年9月2日

适应症

试验速览

暂无简介。

•1.Adults (aged 18 years and over) undergoing percutaneous or hybrid endovascular intervention for CLTI of the lower limbs
•2.Atherosclerosis as the cause of CLTI
•3.Target arteries: infrainguinal (common femoral to pedal) if percutaneous, or iliac to pedal if performed as part of hybrid revascularisation with common femoral endarterectomy
•4.Clinicians would use trial antithrombotic combinations in normal clinical practice
•5.Able to provide informed consent
•6.First time in the CLARITY trial

•1.Open lower-limb bypass as part of hybrid procedure
•2.Pre-existing clinical indication for dual antiplatelet therapy or anticoagulant e.g. atrial fibrillation
•3.Active malignancy or any other non-vascular condition associated with a life expectancy of less than 36 months
•4.Patients undergoing intervention to treat asymptomatic restenosis of a lower-limb bypass graft
•5.Embolic arterial disease
•6.Renal failure with creatinine clearance <15ml/minute
•7.Thrombophilia or any other inherited or acquired bleeding disorders
•8.Persons of childbearing potential who have a positive pregnancy test, are breastfeeding or attempting pregnancy

发起方